Pubmed    Pubmed Central
uBio Home | uBioRSS

WebSearchLiteratureMolecularImages

 uBio  Web Results 1 - 10 of about 2479242

Scientific:
   Acanthospermum humile (low starburr) 
   Ambrosia artemisiifolia (low ragweed) 
   Amelanchier humilis (low serviceberry) 
   Antennaria dimorpha (low pussytoes) 
   Apocynum (low dogbane) 
   Apocynum androsaemifolium pumilum pumilum (low dogbane) 
   Ardisia humilis (low shoebutton) 
   Arenaria humifusa (low sandwort) 
   Argythamnia humilis (low wildmercury) 
   Artemisia arbuscula (low sagebrush) 
   Artemisia arbuscula arbuscula (gray low sagebrush) 
   Asclepias pumila (low milkweed) 
   Asiocolotes depressus (Low Lying Gecko) 
   Aster radula radula (low rough aster) 
   Aster spectabilis (Low Showy Aster) 
   Astragalus lotiflorus (Low milkvetch) 
   Braya humilis (low northern-rockcress) 
   Callirhoe involucrata (low poppymallow) 
   Calystegia spithamaea (low false bindweed) 
   Calystegia spithamaea spithamaea (low false bindweed) 
   Campanula glomerata acaulis (Low Cluster Danesblood Be) 
   Carex concinna (low northern sedge) 
   Carex socialis (low woodland sedge) 
   Chenopodium chenopodioides (low goosefoot) 
   Chrysothamnus humilis (low rabbitbrush) 
   Chrysothamnus molestus (stickyfruit low rabbitbrush) 
   Chrysothamnus viscidiflorus axillaris (low rabbitbrush) 
   Chrysothamnus viscidiflorus lanceolatus (lanceleaf low rabbitbrush) 
   Chrysothamnus viscidiflorus planifolius (flatleaf low rabbitbrush) 
   Chrysothamnus viscidiflorus puberulus (hairy low rabbitbrush) 
   Convolvulus spithamaeus (Low Bindweed) 
   Cornus canadensis (Low Cornel) 
   Crotalaria pumila (low rattlebox) 
   Cryptantha pusilla (low cryptantha) 
   Cyperus pumilus (low flatsedge) 
   Dalea scandens (low prairieclover) 
   Dasyochloa pulchella (low woollygrass) 
   Delphinium nuttallianum (low larkspur) 
   Ericameria nana (low goldenbush) 
   Erigeron pumilus (low fleabane) 
   Euphorbia peplidion (low spurge) 
   Firmicutes (low GC Gram+) 
   Gayophytum humile (low groundsmoke) 
   Gnaphalium uliginosum (low cudweed) 
   Grindelia nana (Low Gumweed) 
   Gypsophila muralis (low babysbreath) 
   Helianthemum propinquum (low frostweed) 
   Hieracium gracile detonsum (low alpine hawkweed) 
   Ipomopsis pumila (low skyrocket) 
   Isolepis cernua (low bulrush) 
   Kyllinga pumila (low spikesedge) 
   Lathyrus pusillus (low peavine) 
   Lesquerella prostrata (low bladderpod) 
   Lupinus pusillus (low lupine) 
   Lythrum ovalifolium (low loosestrife) 
   Malva rotundifolia (low mallow) 
   Menodora heterophylla (low menodora) 
   Muhlenbergia curtifolia (low muhly) 
   Myriophyllum humile (low watermilfoil) 
   Panicum (low panicum sp) 
   Paronychia sessiliflora (low nailwort) 
   Paspalidium (low paspalums) 
   Penstemon humilis (low penstemon) 
   Penstemon humilis humilis (low penstemon) 
   Phacelia humilis (low phacelia) 
   Philonotis fontana caespitosa (low philonotis moss) 
   Polygala ramosa (low pinebarren milkwort) 
   Ranunculus pusillus (low spearwort) 
   Rosa virginiana (Low Rose) 
   Ruellia humilis (low ruellia) 
   Scleria verticillata (low nutrush) 
   Scleropodium cespitans (low scleropodium moss) 
   Senna obtusifolia (Low Senna) 
   Sphagnum compactum (low sphagnum) 
   Thelesperma caespitosum (low greenthread) 
...


Synonyms:
   Asiocolotes depressus (Low Lying Gecko) 

Broader Terms:
   Asiocolotes (Golubev's Geckos) 
   Low 

More Specific:
   Low firmicutes 
   Low gram-positive sulfur-oxidizing 
   Low milkvetch 
   Low squirrel 
   Low threshold vector 
   L÷w pine scale 
   low alpine hawkweed 
   low baby s-breath 
   low babysbreath 
   low bacteria 
   low bacteria walls 
   low bacterium 
   low bacterium wall 
   low beardtongue 
   low bladderpod 
   low bulrush 
   low bush blueberry 
   low catseye 
   low cryptantha 
   low cudweed 
   low daisy 
   low dogbane 
   low everlasting 
   low false bindweed 
   low firmicute environmental samples 
   low flatsedge 
   low fleabane 
   low frostweed 
   low goldenbush 
   low goosefoot 
   low gram-positive cellulolytic thermophile 
   low greenthread 
   low groundsmoke 
   low hop clover 
   low larkspur 
   low loosestrife 
   low lupine 
   low mallow 
   low menodora 
   low milkweed 
   low muhly 
   low nailwort 
   low northern sedge 
   low northern-rockcress 
   low nutrush 
   low panicum 
   low paspalums 
   low peavine 
   low penstemon 
   low phacelia 
   low philonotis moss 
   low pinebarren milkwort 
   low poppymallow 
   low prairie clover 
   low prairieclover 
   low pussytoes 
   low rabbitbrush 
   low ragweed 
   low rattlebox 
   low rough aster 
   low ruellia 
   low sagebrush 
   low sandwort 
   low scleropodium moss 
   low service-berry 
   low serviceberry 
   low shoebutton 
   low silverbush 
   low skyrocket 
   low spearwort 
   low sphagnum 
   low spikesedge 
   low spurge 
   low starburr 
   low water-milfoil 
... 
 
Latest Articles on low from uBioRSS


Chrysothamnus molestus
USDA-NRCS PLANTS Database

External Resources:

Did you mean: Loou, Lou, Louwia, Lova, Love, Lovea, Loveus, Lovia, Lovis, Loviya, Lovor, Lowe, Lowea, Loweia, Lowia or louea?



1.  Repetitive 1.6 ATA hyperbaric oxygen therapy for bilateral ARCO Stage II steroid-associated osteonecrosis of the femoral head.LinkIT
Li H, Bai X, Pan S
Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc, 2020
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0

2.  Pulmonary fluid shifts occur as a result of scuba diving at NASA's Neutral Buoyancy Lab. 531-537 Pulmonary fluid shifts can occur while scuba diving. Such shifts, generally thought to be rare, may result in a life-threatening phenomenon known as immersion pulmonary edema (IPE). This study aims to better classify the normal physiology of diving using ultrasound (US) to determine if these fluid shifts occur routinely during commercial diving work at the NASA Neutral Buoyancy Laboratory (NBL). Chest US was performed on commercial divers prospectively pre- and post-dive to evaluate the presence of B-lines in a total of 12 intercostal points on the anterior, posterior, and lateral chest wall. The number of B-lines at each anatomic site was recorded and scored by two independent reviewers. An increase in the number of B-lines post-dive was considered a positive result. There were 67 exposures; 39 (58%) had an increase of one or more B-lines post dive; 64% of the female exposures and 57% of the male exposures were positive for B-lines post-dive, suggesting no difference across gender (Fisher's exact; p = 0.763). After the dive, all divers remained asymptomatic. From our results, fluid shifts can be viewed as a normal, transient, and physiologic process in commercial divers. This correlation can be compared to the formation of low-grade venous gas emboli (VGE) from decompression that does not result in decompression sickness. Further study of US B-lines in symptomatic divers may define the utility of field US in the diagnosis and management of IPE, and help identify associated risk factors. Copyright┬ę Undersea and Hyperbaric Medical Society. Ray Kristi K Department of Hyperbaric Medicine, Louisiana State University, New Orleans, Louisiana U.S. Williams Sandra S Department of Emergency Medicine, University of Texas Medical Branch, Galveston, Texas U.S. Morrical Stephen S Department of Emergency Medicine, University of Texas Medical Branch, Galveston, Texas U.S. Garbino Alejandro A NASA - Johnson Space Center, Houston, Texas U.S. Hong Michelle M NASA - Department of Emergency Medicine, Baylor College of Medicine, Houston, Texas U.S. Sanders Robert R Medical Director, NASA Neutral Buoyancy Lab, Houston, Texas U.S. eng Journal Article United States Undersea Hyperb Med 9312954 1066-2936 IM S diving enriched air nitrox fluid shifts pulmonary edema ultrasound The authors of this paper declare no conflicts of interest exist with this submission. 2020 11 23 20 17 2020 11 24 6 0 2020 11 24 6 0 ppublish 33227828 33226755 NBK564292 National Library of Medicine (US) Bethesda (MD) Drugs and Lactation Database (LactMed) 2006 2006 Internet Ripretinib eng Review No information is available on the use of ripretinib during breastfeeding. Because ripretinib and its metabolite are more than 99% bound to plasma proteins, the amounts in milk are likely to be low. However, their half-lives are long and the manufacturer recommends that mothers should not breastfeed during treatment with ripretinib and for 1 week after the final dose.
Drug Levels and Effects
Substance Identification
Ripretinib Qinlock DCC-2618 N-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenylurea
2020 11 24 6 1 2020 11 24 6 1 2020 11 24 6 1 ppublish 33226755
33226751 NBK564288 National Library of Medicine (US) Bethesda (MD) Drugs and Lactation Database (LactMed) 2006 2006 Internet Methylnaltrexone eng Review No information is available on the use of methylnaltrexone during breastfeeding. The manufacturer recommends against breastfeeding in mothers taking methylnaltrexone. Based on pharmacokinetic data, the oral absorption of methylnaltrexone appears to be very low. Observe breastfed infants who have been exposed to opioids during pregnancy or postpartum for signs of opioid withdrawal, especially diarrhea.
Drug Levels and Effects
Substance Identification
Methylnaltrexone quaternary ammonium naltrexone (5alpha)-17-(cyclopropylmethyl)-3,14-dihydroxy-17-methyl-4,5-epoxymorphinan-17-ium-6-one 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinanium-6-one morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, (5alpha)- morphinan-17-ium-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-, (5alpha)- naltrexone methylbromide N-methylnaltrexone bromide morphinan-17-ium-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-, bromide, (5alpha,17R)- naltrexone methobromide methylnaltrexone bromide methyl-naltrexone hydrobromide MRZ 2663BR Relistor MRZ-2663
2020 11 24 6 1 2020 11 24 6 1 2020 11 24 6 1 ppublish 33226751
33226749 NBK564286 National Library of Medicine (US) Bethesda (MD) Drugs and Lactation Database (LactMed) 2006 2006 Internet Selpercatinib eng Review No information is available on the use of selpercatinib during breastfeeding. Because selpercatinib is 97% bound to plasma proteins, the amounts in milk are likely to be low. However, the manufacturer recommends that mothers should not breastfeed during treatment with selpercatinib and for 1 week after the final dose.
Drug Levels and Effects
Substance Identification
Selpercatinib LOXO-292 Retevmo 6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitrile Pyrazolo(1,5-a)pyridine-3-carbonitrile, 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxy-3-pyridinyl)methyl)-3,6-diazabicyclo(3.1.1)hept-3-yl)-3-pyridinyl)-
2020 11 24 6 1 2020 11 24 6 1 2020 11 24 6 1 ppublish 33226749
33226747 NBK564284 National Library of Medicine (US) Bethesda (MD) Drugs and Lactation Database (LactMed) 2006 2006 Internet Orphenadrine eng Review No published information is available on the use of orphenadrine during breastfeeding. Manufacturer?s estimates indicate that the amount in milk may be low. The drug?s anticholinergic activity might interfere with milk production. An alternate agent may be preferred.
Drug Levels and Effects
Substance Identification
Orphenadrine Citrate Biorphen Norflex Norgesic Forte Orphengesic Forte BRN 1885151 Brocadisipal BS 5930 Disipal EINECS 201-509-2 HSDB 3139 N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine N,N-Dimethyl-2-(o-methyl-alpha-phenylbenzyl)oxy)ethylamine o-Methyldiphenhydramine o-Monomethyldiphenhydramine Orfenadrina Orphenadinum Orphenadrin Phenyl-o-tolylmethyl dimethyaminoethyl ether
2020 11 24 6 1 2020 11 24 6 1 2020 11 24 6 1 ppublish 33226747
33226746 NBK564283 National Library of Medicine (US) Bethesda (MD) Drugs and Lactation Database (LactMed) 2006 2006 Internet Pralsetinib eng Review No information is available on the use of pralsetinib during breastfeeding. Because pralsetinib is 97% bound to plasma proteins, the amounts in milk are likely to be low. However, the manufacturer recommends that mothers should not breastfeed during treatment with selpercatinib and for 1 week after the final dose.
Drug Levels and Effects
Substance Identification
Pralsetinib Gavreto (cis)-N-((S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide BLU-667 BLU123244 Cyclohexanecarboxamide, N-((1S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)-3-pyridinyl)ethyl)-1-methoxy-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)-, cis-
2020 11 24 6 1 2020 11 24 6 1 2020 11 24 6 1 ppublish 33226746
33226744 NBK564281 National Library of Medicine (US) Bethesda (MD) Drugs and Lactation Database (LactMed) 2006 2006 Internet Bamlanivimab eng Review Bamlanivimab is a monoclonal antibody directed against the SARS-CoV-2 virus that causes COVID-19. No information is available on the clinical use of bamlanivimab during breastfeeding. Because bamlanivimab is a large protein molecule with a molecular weight of 146,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, bamlanivimab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Bamlanivimab is a human immunoglobulin G1 (IgG1) kappa antibody. Holder pasteurization (62.5 degrees C for 30 minutes) decreases the concentration of endogenous immunoglobulin G by up to 79%.[1,2] A study of 67 colostrum samples that underwent Holder pasteurization found that IgG amounts decreased by 34 to 40%. Specific IgG subclasses decreased by different amounts, with IgG1 activity decreasing by about 37%.[3] None of the studies measured IgG activity.
Drug Levels and Effects
Substance Identification
Bamlanivimab LY-3819253 LY-COV555 LY3819253 UNII-45I6OFJ8QH
2020 11 24 6 1 2020 11 24 6 1 2020 11 24 6 1 ppublish 33226744
33226742 NBK564279 National Library of Medicine (US) Bethesda (MD) Drugs and Lactation Database (LactMed) 2006 2006 Internet Casirivimab eng Review Casirivimab is a monoclonal antibody given together with imdevimab. Both are directed against the SARS-CoV-2 virus that causes COVID-19. No information is available on the clinical use of casirivimab during breastfeeding. Because casirivimab is a large protein molecule with a molecular weight of over 145,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, casirivimab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Casirivimab is a human immunoglobulin G1 (IgG1) antibody. Holder pasteurization (62.5 degrees C for 30 minutes) decreases the concentration of endogenous immunoglobulin G by up to 79%.[1,2] A study of 67 colostrum samples that underwent Holder pasteurization found that IgG amounts decreased by 34 to 40%. Specific IgG subclasses decreased by different amounts, with IgG1 activity decreasing by about 37%.[3] None of the studies measured IgG activity.
Drug Levels and Effects
Substance Identification
Casirivimab REGN-10933 REGN10933 UNII-J0FI6WE1QN
2020 11 24 6 1 2020 11 24 6 1 2020 11 24 6 1 ppublish 33226742
33226741 NBK564278 National Library of Medicine (US) Bethesda (MD) Drugs and Lactation Database (LactMed) 2006 2006 Internet Imdevimab
LinkIT
Ray K, Williams S, Morrical S, Garbino A, Hong M, Sanders R
Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc, 2020 11 23 20 17 2020 11 24 6 0 2020 11 24 6 0 ppublish 33227828 33226755 NBK564292 National Library of Medicine (US) Bethesda (MD) Drugs and Lactation Database (LactMed) 2006 2006 Internet Ripretinib eng Review No information is available on the use of ripretinib during breastfeeding. Because ripretinib and its metabolite are more than 99% bound to plasma proteins, the amounts in milk are likely to be low. However, their half-lives are long and the manufacturer recommends that mothers should not breastfeed during treatment with ripretinib and for 1 week after the final dose.
Drug Levels and Effects
Substance Identification
Ripretinib Qinlock DCC-2618 N-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenylurea
2020 11 24 6 1 2020 11 24 6 1 2020 11 24 6 1 ppublish 33226755
33226751 NBK564288 National Library of Medicine (US) Bethesda (MD) Drugs and Lactation Database (LactMed) 2006 2006 Internet Methylnaltrexone eng Review No information is available on the use of methylnaltrexone during breastfeeding. The manufacturer recommends against breastfeeding in mothers taking methylnaltrexone. Based on pharmacokinetic data, the oral absorption of methylnaltrexone appears to be very low. Observe breastfed infants who have been exposed to opioids during pregnancy or postpartum for signs of opioid withdrawal, especially diarrhea.
Drug Levels and Effects
Substance Identification
Methylnaltrexone quaternary ammonium naltrexone (5alpha)-17-(cyclopropylmethyl)-3,14-dihydroxy-17-methyl-4,5-epoxymorphinan-17-ium-6-one 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinanium-6-one morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, (5alpha)- morphinan-17-ium-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-, (5alpha)- naltrexone methylbromide N-methylnaltrexone bromide morphinan-17-ium-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-, bromide, (5alpha,17R)- naltrexone methobromide methylnaltrexone bromide methyl-naltrexone hydrobromide MRZ 2663BR Relistor MRZ-2663
2020 11 24 6 1 2020 11 24 6 1 2020 11 24 6 1 ppublish 33226751
33226749 NBK564286 National Library of Medicine (US) Bethesda (MD) Drugs and Lactation Database (LactMed) 2006 2006 Internet Selpercatinib eng Review No information is available on the use of selpercatinib during breastfeeding. Because selpercatinib is 97% bound to plasma proteins, the amounts in milk are likely to be low. However, the manufacturer recommends that mothers should not breastfeed during treatment with selpercatinib and for 1 week after the final dose.
Drug Levels and Effects
Substance Identification
Selpercatinib LOXO-292 Retevmo 6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitrile Pyrazolo(1,5-a)pyridine-3-carbonitrile, 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxy-3-pyridinyl)methyl)-3,6-diazabicyclo(3.1.1)hept-3-yl)-3-pyridinyl)-
2020 11 24 6 1 2020 11 24 6 1 2020 11 24 6 1 ppublish 33226749
33226747 NBK564284 National Library of Medicine (US) Bethesda (MD) Drugs and Lactation Database (LactMed) 2006 2006 Internet Orphenadrine eng Review No published information is available on the use of orphenadrine during breastfeeding. Manufacturer?s estimates indicate that the amount in milk may be low. The drug?s anticholinergic activity might interfere with milk production. An alternate agent may be preferred.
Drug Levels and Effects
Substance Identification
Orphenadrine Citrate Biorphen Norflex Norgesic Forte Orphengesic Forte BRN 1885151 Brocadisipal BS 5930 Disipal EINECS 201-509-2 HSDB 3139 N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine N,N-Dimethyl-2-(o-methyl-alpha-phenylbenzyl)oxy)ethylamine o-Methyldiphenhydramine o-Monomethyldiphenhydramine Orfenadrina Orphenadinum Orphenadrin Phenyl-o-tolylmethyl dimethyaminoethyl ether
2020 11 24 6 1 2020 11 24 6 1 2020 11 24 6 1 ppublish 33226747
33226746 NBK564283 National Library of Medicine (US) Bethesda (MD) Drugs and Lactation Database (LactMed) 2006 2006 Internet Pralsetinib eng Review No information is available on the use of pralsetinib during breastfeeding. Because pralsetinib is 97% bound to plasma proteins, the amounts in milk are likely to be low. However, the manufacturer recommends that mothers should not breastfeed during treatment with selpercatinib and for 1 week after the final dose.
Drug Levels and Effects
Substance Identification
Pralsetinib Gavreto (cis)-N-((S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide BLU-667 BLU123244 Cyclohexanecarboxamide, N-((1S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)-3-pyridinyl)ethyl)-1-methoxy-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)-, cis-
2020 11 24 6 1 2020 11 24 6 1 2020 11 24 6 1 ppublish 33226746
33226744 NBK564281 National Library of Medicine (US) Bethesda (MD) Drugs and Lactation Database (LactMed) 2006 2006 Internet Bamlanivimab eng Review Bamlanivimab is a monoclonal antibody directed against the SARS-CoV-2 virus that causes COVID-19. No information is available on the clinical use of bamlanivimab during breastfeeding. Because bamlanivimab is a large protein molecule with a molecular weight of 146,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, bamlanivimab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Bamlanivimab is a human immunoglobulin G1 (IgG1) kappa antibody. Holder pasteurization (62.5 degrees C for 30 minutes) decreases the concentration of endogenous immunoglobulin G by up to 79%.[1,2] A study of 67 colostrum samples that underwent Holder pasteurization found that IgG amounts decreased by 34 to 40%. Specific IgG subclasses decreased by different amounts, with IgG1 activity decreasing by about 37%.[3] None of the studies measured IgG activity.
Drug Levels and Effects
Substance Identification
Bamlanivimab LY-3819253 LY-COV555 LY3819253 UNII-45I6OFJ8QH
2020 11 24 6 1 2020 11 24 6 1 2020 11 24 6 1 ppublish 33226744
33226742 NBK564279 National Library of Medicine (US) Bethesda (MD) Drugs and Lactation Database (LactMed) 2006 2006 Internet Casirivimab eng Review Casirivimab is a monoclonal antibody given together with imdevimab. Both are directed against the SARS-CoV-2 virus that causes COVID-19. No information is available on the clinical use of casirivimab during breastfeeding. Because casirivimab is a large protein molecule with a molecular weight of over 145,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, casirivimab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Casirivimab is a human immunoglobulin G1 (IgG1) antibody. Holder pasteurization (62.5 degrees C for 30 minutes) decreases the concentration of endogenous immunoglobulin G by up to 79%.[1,2] A study of 67 colostrum samples that underwent Holder pasteurization found that IgG amounts decreased by 34 to 40%. Specific IgG subclasses decreased by different amounts, with IgG1 activity decreasing by about 37%.[3] None of the studies measured IgG activity.
Drug Levels and Effects
Substance Identification
Casirivimab REGN-10933 REGN10933 UNII-J0FI6WE1QN
2020 11 24 6 1 2020 11 24 6 1 2020 11 24 6 1 ppublish 33226742
33226741 NBK564278 National Library of Medicine (US) Bethesda (MD) Drugs and Lactation Database (LactMed) 2006

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0



1